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Experimental evidence suggests that aldosterone contributes
to progressive kidney disease. Angiotensin-converting
enzyme inhibitors and angiotensin type 1 receptor
antagonists suppress the renin–angiotensin system but
they do not effectively reduce plasma aldosterone. Hence,
administration of aldosterone receptor antagonists may
provide additional renal protection. In the present
prospective randomized open-label study, we evaluated
the effects of spironolactone (25 mg/day for 1 year) on
proteinuria and estimated glomerular filtration rate in
83 patients with chronic kidney disease already treated
with angiotensin-converting enzyme inhibitors and/or
angiotensin type 1 receptor antagonists. Eighty-two patients
were treated with angiotensin-converting enzyme inhibitors
and/or angiotensin type 1 receptor antagonists alone and
served as controls. After 1 year of therapy, proteinuria
decreased from 2.170.08 to 0.8970.06 g/g creatinine
(Po0.001) in patients treated with spironolactone, but it did
not change in control patients. Baseline aldosterone levels
were significantly correlated with proteinuria (r¼ 0.76,
Po0.0001), and predicted the degree of reduction in
proteinuria with spironolactone (r¼ 0.42, Po0.0002).
Baseline estimated glomerular filtration rate was similar in
patients treated with spironolactone and controls (62.472.4
and 62.272.1 ml/min/1.73 m2, respectively). After 1 month of
therapy with spironolactone, estimated glomerular filtration
rate decreased more in patients treated with spironolactone
than in controls. However, by the end of 1 year the monthly
rate of decrease in estimated glomerular filtration rate from
baseline was lower in patients treated with spironolactone
than in controls (0.32370.044 vs 0.47470.037 ml/min/
1.73 m2, Po0.01). Spironolactone caused a significant rise
in serum potassium levels (from 4.270.04 at baseline to
5.070.05 mEq/l after 12 months of treatment, Po0.001). In
conclusion, this study has shown that spironolactone may
reduce proteinuria and retard renal progression in chronic
kidney disease patients.
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Background
The prevalence of chronic kidney disease (CKD) is increasing
alarmingly mainly as a result of an ongoing epidemic of
obesity, metabolic syndrome, and diabetes mellitus.1
Several factors may contribute to the progression of CKD
including derangements of renal hemodynamics, vasoactive
hormones such as angiotensin II and norepinephrine,
cytokines, growth factors, oxidative stress, and inflamma-
tion.2–4 Numerous studies have demonstrated that the
renin–angiotensin–aldosterone system (RAAS) plays an im-
portant role in the progression of CKD,5,6 and inhibition of
the RAAS with angiotensin-converting enzyme inhibitors
(ACEIs) and angiotensin type 1 receptor antagonists (ARBs)
may retard CKD progression.7–10 These renoprotective effects
are attributed to reduction of systemic arterial and
glomerular pressures and to inhibition of angiotensin-II-
related effects on mesangial cell proliferation and fibrosis.11
However, neither ACEIs nor ARBs abrogate the progression
of kidney disease. This suggests that ACEIs and ARBs, at the
doses currently approved, do not predictably suppress
aldosterone in all patients, a phenomenon known as
‘aldosterone synthesis escape,’ leaving potentially detrimental
effects of aldosterone unabated.12
Studies in experimental rat models have shown that
aldosterone participates to the progression of kidney disease
through hemodynamic and direct cellular actions13 and
antagonists of aldosterone retard the progression or cause
regression of existing glomerulosclerosis independently of
effects on blood pressure (BP).14–16
The clinical evidence for a role of aldosterone in CKD
progression is scanty.17–20 In a pilot short-term uncontrolled
study, we observed that spironolactone effectively reduced
proteinuria in non-diabetic CKD patients already treated
with ACEIs and/or ARBs.21
This is a prospective, randomized open-label study to
evaluate the effects of spironolactone, an aldosterone receptor
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antagonist, on proteinuria and estimated glomerular filtra-
tion rate (eGFR) in a cohort of 165 CKD patients treated for
1 year.
RESULTS
The baseline and follow-up clinical characteristics of all
patients included in the study are shown in Tables 1 and 2.
The baseline clinical characteristics of patients treated
with spironolactone did not differ from those of patients
treated with conventional therapy. Baseline proteinuria was
2.170.08 g/g creatinine in patients treated with spirono-
lactone and 2.070.07 g/g creatinine in patients treated with
conventional therapy. After 1 year of follow-up, proteinuria
decreased to 0.8970.06 g/g creatinine among patients treated
with spironolactone, but it did not change among patients
treated with conventional therapy (Table 3). In 23 out of 78
patients treated with spironolactone for 1 year, proteinuria
decreased to o500 mg/g creatinine. Baseline proteinuria was
greater among patients with eGFRo60 ml/min/1.73 m2 than
among those with eGFR460 ml/min/1.73 m2 (2.1770.08 vs
1.8270.07 g/g creatinine in the conventional therapy group
and 2.3370.09 vs 1.8470.08 g/g creatinine in the group of
patients treated with spironolactone) (Table 3). After 1 year
of treatment with spironolactone, the percent decline in
proteinuria was significantly greater among patients with
estimated GFRo60 than among patients with estimate
GFR460 ml/min/1.732 (62.2 vs42.9%, Po0.01) (Table 3,
Figure 1).
After 1 year of treatment with spironolactone, the percent
reduction in proteinuria was greater among patients treated
with ACEIs (60.974.8%) or ARBs alone (67.973.6%)
than among patients treated with a combination of ACEIs
and ARBs (42.875.5%, Po0.01) (Table 5).
After 4 weeks of treatment with spironolactone, eGFR
decreased from 62.472.4 to 57.372.7 ml/min/1.732
(Po0.001) (Table 4). Thereafter, eGFR remained stable and
at the end of 12 months treatment was 58.672.6 ml/min/
1.732. By contrast, during 1 year of follow-up, eGFR declined
slowly but progressively in subjects treated with conventional
therapy (from 62.272.1 to 56.472.3 ml/min/1.732, Po0.01)
(Table 4, Figure 2). At the end of 1 year of treatment,
eGFR was not statistically different between the two groups.
However, the percent decline in eGFR was lower in patients
treated with spironolactone than in controls (Figure 2). Also,
the monthly rate of decrease in eGFR from baseline was lower
in patients treated with spironolactone than in controls
(0.32370.044 vs 0.47470.037 ml/min, Po0.01). The reduc-
tion in eGFR observed during treatment with spironolactone
was more pronounced among patients with estimated
GFRo60 ml/min than among patients with GFR460 ml/
min/1.73 m2 (Table 4). After 1 year of treatment, we observed
a weak but statistically significant correlation between the
percent changes in proteinuria and changes in eGFR in the
entire group of patients studied (r¼ 0.307 Po0.0001). This
relationship was significant only for patients treated with
spironolactone (r¼ 0.350, Po0.0001) and not for patients
treated with conventional therapy. The relationship between
the percent change in proteinuria and change in eGFR
was already present after the first month of treatment with
spironolactone (r¼ 0.436, Po0.0001).
Table 1 | Clinical characteristics at baseline of patients treated with conventional therapy and those receiving conventional
therapy plus spironolactone 25 mg/day
All Conventional therapy Conventional therapy plus spironolactone
No. of patients 165 82 83
Age (years) 54.770.8 54.471.2 55.071.2
Sex (M/F) 106/59 50/32 56/27
BMI 24.970.2 24.870.2 24.970.2
Smokers (Y/N) 41/124 21/61 19/64
Basal SBP (mmHg) 132.370.5 131.670.6 132.970.8
Basal DBP (mmHg) 78.370.3 78.170.4 78.570.5
eGFR (ml/min/1.73 m2) 62.371.6 62.272.1 62.472.4
Uprotein (g/g creatinine) 2.170.05 2.070.07 2.170.08
Serum K+ (mEq/l) 4.370.03 4.270.03 4.270.04
Basal aldosterone (pg/ml) 132.174.7 130.476.5 134.776.9
Antihypertensive drugs
ACEIs 50 21 29
ARBs 35 18 17
Both ACEIs and ARBs 80 43 37
Other antihypertensive drugs
Number (O/1/2/3) 20/69/60/16 8/36/34/4 12/33/26/12
Diuretics (Y/N) 116/49 56/26 60/23
Statins (Y/N) 146/19 72/10 74/9
ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin type 1 receptor antagonists; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood
pressure; F, female; M, male; K+, potassium; N, no; Y, yes; eGFR; estimated glomerular filtration rate.
Data are expressed as mean7s.e.m.
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Baseline BP in patients randomized to conventional
therapy was 131.670.6/78.170.4 mmHg and in patients
randomized to spironolactone was 132.970.8/78.57
0.5 mmHg. After 9 and 12 months of therapy with spiro-
nolactone, BP decreased (Po0.05) in patients treated with
spironolactone (128.370.8/76.370.5 and 126.970.8/75.670.5,
respectively) but not in the control group (130.570.6/77.570.5
and 130.270.6/78.170.7, respectively) (Table 2). No
effect of spironolactone on BP was evident during the first
6 months of treatment.
Baseline serum potassium was not different between
patients treated with conventional therapy and those rando-
mized to spironolactone (4.270.03 and 4.270.04 mEq/l,
respectively) (Table 2). However, during treatment with
spironolactone, serum potassium increased progressively
from 4.270.04 at baseline to 5.070.05 mEq/l (Po0.001) at
the end of 1 year of treatment. By contrast, serum potassium
did not change in patients treated with conventional therapy.
Four patients in the spironolactone arm and two in the
conventional therapy arm of the study, all with estimated
GFRo60 ml/min, reached a serum potassium level 45.5 but
o6.0 mEq/l and had to discontinue the study. Baseline serum
potassium levels were higher (Po0.005) in patients treated
with a combination of ACEIs and ARBs (4.470.07 mEq/l)
than in those treated with ARBs alone (4.270.08 mEq/l).
Baseline serum potassium levels were not different in patients
treated with a combination of ACEIs and ARBs (4.47
0.07 mEq/l) than in those treated with ACEIs alone (4.37
0.08 mEq/l) (Table 5). The effects of spironolactone treat-
ment on serum Kþ were not different in patients treated
with a combination of ACEIs and ARBs than in those treated
with ACEIs or ARBs alone (Table 5).
Baseline plasma aldosterone levels were not different
between patients treated with conventional therapy and
those randomized to spironolactone (130.476.5 and 134.77
6.9 pg/ml, respectively). Aldosterone levels were lower
(Po0.001) among the 35 patients receiving ACEIs and ARBs
combined (89.674.9 pg/ml) than the 27 patients receiving
ACEIs alone (165.777 pg/ml) and the 16 patients receiving
ARBs alone (18179.7 pg/ml) (Table 5).
Baseline levels of aldosterone were significantly correlated
with levels of proteinuria (r¼ 0.766, Po0.0001) (Figure 3)
Table 2 | Blood pressure, estimated GFR and serum potassium
levels at baseline and during follow-up in patients treated
with conventional therapy and those treated with
conventional therapy plus spironolactone
Conventional
therapy
Conventional
therapy plus
spironolactone
Blood pressure (mmHg)
Basal SBP 131.670.6 132.970.8
Basal DBP 78.170.4 78.570.5
1 month
SBP 130.870.6 131.470.8
DBP 77.370.7 77.870.5
3 months
SBP 130.770.6 131.370.9
DBP 76.570.9 78.370.6
6 months
SBP 130.370.6 129.570.9
DBP 76.570.9 76.970.6
9 months
SBP 130.570.6 128.570.9*
DBP 77.570.5 76.570.5**
12 months
SBP 130.270.6 126.970.8**,#
DBP 77.370.5 75.670.5**,@
Estimated GFR (ml/min/1.73 m2)
Basal 62.272.1 62.472.4
1 month 61.172.2 57.372.7*
3 months 59.772.3 56.672.7*
6 months 58.672.2* 57.872.7*
9 months 57.472.3* 58.072.6*
12 months 56.472.3** 58.672.6*
Serum potassium (mEq/l)
Basal 4.270.03 4.270.04
1 month 4.370.03 4.570.05**,#
3 months 4.370.04 4.770.05**,#
6 months 4.370.05 4.770.07**,#
9 months 4.370.05 4.870.05**,#
12 months 4.370.05 5.070.05**,#
DBP, diastolic blood pressure; GFR, glomerular filtration rate; SBP, systolic blood
pressure.
Data are expressed as mean7s.e.m.
*Po0.05 vs basal.
**Po0.001 vs basal.
#Po0.001 vs conventional therapy.
@Po0.03 vs conventional therapy.
Table 3 | Effect of spironolactone on proteinuria in patients
with eGFRo or 460 ml/min/1.73 m2
Conventional
therapy
Conventional
therapy plus
spironolactone
Basal all 2.070.07 2.170.08
eGFRo60 ml/min 2.1770.08 2.3370.09
eGFR460 ml/min 1.8270.07** 1.8470.08**
1 month all 2.070.07 1.4970.06 (26.9%)*
eGFRo60 ml/min 2.1670.08 1.6270.09 (29.8%)
eGFR460 ml/min 1.8970.07 1.3170.07 (22.8%)
3 months all 1.9770.07 1.2670.06 (37.9%)*
eGFRo60 ml/min 2.0170.08 1.3470.09 (42.3%)
eGFR460 ml/min 1.8970.07 1.1570.07 (31.5)**
6 months all 1.9770.07 1.1370.06 (43.9%)*
eGFRo60 ml/min 2.1470.08 1.1970.09 (48.5%)
eGFR460 ml/min 1.8670.07 1.0570.08 (37.2%)#
9 months all 2.070.07 0.9970.06 (49.9%)*
eGFRo60 ml/min 2.170.08 1.070.08 (56.4%)
eGFR460 ml/min 1.9470.07 0.9870.08 (40.%)**
12 months all 2.1170.08 0.8970.06 (54.2%)*
eGFRo60 ml/min 2.1970.09 0.8870.09 (62.2%)
eGFR460 ml/min 1.9970.08 0.9370.09 (42.9%)**
eGFR, estimated glomerular filtration rate.
In parentheses are the % changes vs basal proteinuria.
*Po0.001 vs basal proteinuria.
#Po0.05 vs patients with eGFRo60 ml/min.
**Po0.01 vs patients with eGFRo60 ml/min.
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and with the percent reduction in proteinuria following
treatment with spironolactone (r¼ 0.42, Po0.0002).
Single regression analyses showed that the level of urine
protein excretion at 12 months was significantly correlated
with systolic (r¼ 0.272, Po0.001) and diastolic BP (r¼
0.242, Po0.002), and with the change in eGFR after 1 month
of treatment with spironolactone (r¼ 0.459, Po0.0001).
Table 4 | Effect of spironolactone 25 mg/day on renal function
in patients with eGFRo or 460 ml/min/1.73 m2
Conventional
therapy
Conventional
therapy plus
spironolactone
Basal eGFR 62.272.1 62.472.4
eGFRo60 ml/min 49.571.7 46.571.3
eGFR460 ml/min 80.172.2 85.372.3
1 month 61.172.2 57.372.7#
% Reduction vs basal
All patients 1.67/0.2 8.270.8#
eGFRo60 ml/min 2.370.3 13.670.8#
eGFR460 ml/min 0.770.3 4.170.9*
3 months eGFR 59.772.3 56.672.7#
% Reduction vs basal
All patients 3.670.4 9.170.8#
eGFRo60 ml/min 5.670.5 15.170.9#
eGFR460 ml/min 1.870.4 4.670.9*
6 months eGFR 58.672.2# 57.872.7
% Reduction vs basal
All patients 5.570.4# 7.570.8#
eGFRo60 ml/min 8.270.5# 12.870.9#
eGFR460 ml/min 3.170.5* 3.470.7*
9 months eGFR 57.472.3# 58.072.6#
% Reduction vs basal
All patient 7.470.6# 7.270.7#
eGFRo60 ml/min 11.470.6# 10.070.9#
eGFR460 ml/min 4.370.7* 4.270.7*
12 months eGFR 56.472.3# 58.672.6#
% Reduction vs basal
All patient 9.070.6#,# 6.270.7#
eGFRo60 ml/min 13.570.7# 8.170.9#
eGFR460 ml/min 5.770.7* 3.970.7*
eGFR, estimated glomerular filtration rate (ml/min/1.73 m2) by Modification of Diet
in Renal Disease formula.
*Po0.01 vs patients with eGFRo60 ml/min; #Po0.001 vs baseline eGFR.
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Figure 1 | This slide shows the percent reduction of proteinuria
from baseline in patients treated with spironolactone (25 mg/
day) in addition to conventional therapy divided on the basis
of their eGFR (o or 460 ml/min/1.73 m2). *Po0.001 vs basal
proteinuria; #Po0.05 vs patients with eGFR o60 ml/min; @Po0.01
vs patients with eGFR o60 ml/min.
Table 5 | Clinical characteristics at baseline and end of the
study in patients treated with spironolactone in addition to
ACEIs alone, ARBs alone, or a combination of ACEIs and ARBs
ACEIs ARBs ACEIs+ARBs
No. of patients 27 16 35
Age 57.672.1 53.372.9 53.771.7
Sex (M/F) 17/10 11/5 25/10
BMI 24.970.5 24.870.6 24.970.3
Other antihypertensive drugs
(O/1/2/3) 2/16/6/3 3/8/3/2 6/7/16/6
Diuretics (Y/N) 19/8 10/6 22/13
Statins (Y/N) 25/2 14/2 32/3
Basal aldosterone (pg/ml) 165.777 18179.7 89.674.9*
Basal SBP (mmHg) 132.871.9 136.571.7 131.371.3
Basal DBP (mmHg) 78.470.8 80.370.9 77.770.9
Basal serum potassium (mEq/l) 4.370.08 4.270.08 4.470.07**
% Increase at 12 months 5.070.08 4.870.07 5.170.09**
Basal proteinuria (g/g creatinine) 2.3870.1 2.7970.1 1.5970.09#
% Reduction at 12 months 60.974.8 67.973.6 42.875.5*
Basal eGFR (ml/min/1.73 m2) 55.573.6 58.474.9 69.774*
% Reduction at 12 months 6.771.3 8.171.4 6.771.5
ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin type 1 receptor
antagonists; BMI, body mass index; DBP, diastolic blood pressure; F, female; M, male;
N, no; SBP, systolic blood pressure; Y, yes.
*Po0.01 vs patients treated with ACEIs or ARBs alone.
#Po0.05 vs patients treated with ACEIs and ARBs.
**Po0.005 vs patients treated with ARBs.
Five of the original patients randomized to spironolactone did not complete the
study owing to adverse events. These patients are not included in this analysis.
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Figure 2 | This slide shows the percent decline in eGFR in patients
treated with spironolactone and those treated with conventional
therapy. Patients were followed for 1 year. *Po0.001 vs basal eGFR,
**Po0.0001 vs basal eGFR.
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Step-wise multiple linear regression analyses using 12
months percentage reduction of proteinuria as a dependent
variable and systolic and diastolic BP, plasma aldosterone,
eGFR, and baseline proteinuria as independent explanatory
variables showed that systolic BP at 12 months (P¼ 0.02),
basal aldosterone (P¼ 0.017), and the percent change in
eGFR at 1 month (P¼ 0.004), but not eGFR at 12 months
(P¼ 0.06) and basal proteinuria (P¼ 0.56) predicted the
reduction in proteinuria with spironolactone treatment.
Adverse events and dropouts
Nine patients did not complete the study, five in the
spironolactone group and four in the control group. In the
spironolactone group, four patients discontinued treatment
after 3 months because of persistent serum Kþ45.5 mEq/l
despite diuretic therapy and low Kþ diet. All these subjects
had eGFRo60 ml/min/1.73 m2 and three out of four were
taking a combination of ACEIs and ARBs; the fourth patient
was taking an ACEI. One patient developed significant
gynecomastia and discontinued treatment after 3 months.
Five additional patients treated with spironolactone devel-
oped mild gynecomastia that did not necessitate disconti-
nuation of the drug. In the control group, four patients
discontinued therapy during the first 3 months, two for
hyperkalemia, and two were lost to follow-up. All patients
with hyperkalemia had baseline eGFRo60 ml/min/1.732.
DISCUSSION
In this long-term study, we have confirmed that spirono-
lactone can substantially reduce urine protein excretion in
patients with CKD. This effect occurred in patients with the
RAAS inhibited by ACEIs and/or ARBs for at least 1 year
before the initiation of treatment with spironolactone and it
was sustained throughout the period of observation.
In a previous study, we showed that treatment with 25 mg
of spironolactone for 8 weeks reduced proteinuria from
2.0970.16 to 1.0570.08 g/24 h. The reduction in proteinuria
was apparent as early as 2 weeks after initiation of treatment
and reverted to baseline 4 weeks after discontinuation of
the drug.21
The observed early reduction in proteinuria was not
related to changes in BP since it was evident after 1 month of
treatment with spironolactone, at a time when there was no
significant change in BP. Significant effects of spironolactone
on BP became evident only after 9 and 12 months of
treatment. After 12 months, multiple regression analyses
showed a contribution of BP to proteinuria reduction.
Chrysostomou et al.22 observed a 50% decrease in proteinur-
ia in CKD patients without significant changes in BP.
The baseline levels of proteinuria were lower among
patients treated with a combination of ACEIs and ARBs than
among those treated with any of these drugs alone. This is in
line with the study of Nakao et al.23 who showed greater
reduction of proteinuria with a combination of trandolapril
and losartan than with any of these drugs alone23 and
suggests that ACEIs and ARBs when given alone even at the
highest approved doses may provide incomplete RAAS block-
ade. The beneficial effects of spironolactone on proteinuria in
patients with already suppressed RAAS by ACEIs or ARBs can
be best explained by inadequate suppression of aldosterone
secretion.24 The percent decline in proteinuria with spirono-
lactone was less pronounced among patients who received a
combination of ACEIs and ARBs than among patients who
received ACEIs or ARBs alone. It is noteworthy that the
baseline levels of aldosterone were lower among patients
treated with a combination of ACEI and ARBs than among
patients treated with any of these classes of drugs alone. This
is in keeping with the notion that levels of aldosterone are an
important determinant of the degree of proteinuria and of
the pharmacological response to spironolactone in CKD
patients. In support of this hypothesis is also the strong
correlation we observed between baseline levels of aldoster-
one and levels of proteinuria.
Before this study, there was limited evidence that
antagonists of aldosterone reduce proteinuria in CKD
patients. In an uncontrolled trial of eight patients with
various renal diseases and proteinuria 41 g per day, spiro-
nolactone consistently reduced proteinuria.25 In 13 patients
with early diabetic nephropathy and ‘aldosterone escape’
from ACEIs, Sato et al.20 observed a significant reduction
in urinary albumin excretion after 24 week of treatment
with spironolactone. Of note, the decrease in urine albumin
excretion was more pronounced among patients with aldo-
sterone escape. Rachmani et al.19 compared the antiprotei-
nuric effects of spironolactone with that of cilazapril in 60
female with diabetic nephropathy. Spironolactone reduced
proteinuria more effectively than ACEIs and the combined
administration of the ACEIs and spironolactone was more
effective than either drug alone. Epstein et al.26 observed that
eplerenone reduced proteinuria more effectively than an
ACEI in patients with type II diabetes mellitus and the combi-
nation of eplerenone and ACEI was more effective than either
drug given alone in reducing proteinuria. Spironolactone
treatment in addition to recommended antihypertensive
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Figure 3 | This slide shows the regression line between baseline
plasma aldosterone levels and proteinuria in the 165 patients
included in the study (r¼ 0.766, Po0.0001).
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drugs reduced BP and proteinuria in type I and type II
diabetic patients with nephropathy.27,28
This study is also the first to suggest that spironolactone
may reduce the rate of decline in kidney function in CKD
patients. Baseline eGFR was not different in the two groups of
patients studied. However, in patients treated with spirono-
lactone we observed an initial rapid (after 1 month) decline
in eGFR, followed by stabilization. By contrast, in patients
treated with conventional therapy, eGFR declined slowly but
progressively. By the end of 1-year treatment, the percent
decline in eGFR was significantly greater in patients treated
with conventional therapy than in those treated with
spironolactone.
The mechanisms responsible for the initial acute reduc-
tion in eGFR are unclear. However, this phenomenon is
reminiscent of the initial fall in eGFR seen in CKD patients
treated with ACEIs, whereby an initial rapid decrease in GFR
is usually followed by stabilization of kidney function.7
Schmidt et al.29 have shown that aldosterone exerts rapid
nongenomic effects on the renal vasculature resulting in
increased renal vascular resistance and increased filtration
fraction. These effect of aldosterone on the renal vasculature
occurred only when endothelial NO synthase was inhibited
by simultaneous administration of NG monomethyl-L-
arginine. In an editorial accompanying the article by Schmidt
et al.,29 Chun and Pratt30 suggest that under conditions of
endothelial dysfunction, as it might occur in patients with
essential hypertension, metabolic syndrome, or CKD, these
nongenomic effects of aldosterone might result in reduced
renal blood flow and GFR. Using isolated afferent and
efferent arterioles from rabbit kidneys, Arima et al.31 have
shown that aldosterone exerts a vasoconstrictive action on
both the afferent and efferent arterioles, but the sensitivity
of the efferent arterioles to aldosterone was greater than that
of the afferent arterioles. Interestingly, the vasoconstrictor
effects of aldosterone were not blocked by spironolactone
suggesting that the vasoconstrictor action is non-genomic.
Endothelial denudation and pharmacological blockade of
eNOS increased the sensitivity of the afferent arterioles
to aldosterone suggesting that nitric oxide modulates the
vasoconstrictor action of aldosterone.32 In a dog model of
obesity-induced hypertension, both BP and GFR decreased
after treatment with eplerenone.33 In all, these studies suggest
that antagonists of aldosterone may exert intrarenal hemo-
dynamic changes resulting in an acute decrease in GFR.
After this initial rapid fall, eGFR remained stable
throughout the rest of the year of treatment with spirono-
lactone and the average percent decline in eGFR was signi-
ficantly lower in patients treated with spironolactone than in
those treated with conventional therapy. These findings are
consistent with the wealth of experimental evidence showing
aldosterone may contribute to renal injury34,35 and antago-
nists of this hormone may result in renal protection. In 5/6
nephrectomized rats with subtotal nephrectomy and adrenal-
ectomy, proteinuria hypertension and structural renal injury
were less pronounced than in rats with intact adrenal
glands.36 Aldosterone infusion abrogated the beneficial effects
of ACEIs in stroke-prone spontaneously hypertensive rats,
whereas spironolactone reduced vascular injury and protein-
uria in these animals.14,15
The mechanisms responsible for the adverse effects of
aldosterone on the kidney are complex. As a result of
differential effects on the afferent and efferent glomerular
arterioles, aldosterone could increase intraglomerular pres-
sure, an action reminiscent of that of angiotensin II. Experi-
mental evidence has shown that aldosterone may damage
non-epithelial tissues, in the heart, brain, kidneys, and blood
vessels.37–42 Aldosterone stimulates type IV collagen accu-
mulation in rat mesangial cells and this may result in
progressive renal fibrosis.43 Aldosterone stimulates plasmino-
gen activator inhibitor-1, which is centrally involved in the
pathogenesis of fibrinolysis and it may contribute to
glomerulosclerosis and tubulo-interstitial nephritis.44,45
Aldosterone stimulates transforming growth factor-b1, a
cytokine that promotes fibroblast differentiation and pro-
liferation,46 and aldosterone antagonists improve experimen-
tal chronic cyclosporine nephrotoxicity.47 Eplerenone inhibits
lectine-like oxidized low-density lipoprotein receptor-1-
mediated adhesion molecules and results in improved endo-
thelial function.48 In 4-week-old Dahl’s salt-sensitive rats
fed high-salt diet, Nagase et al.49 observed proteinuria and
glomerulosclerosis associated with a decrease in nephrin and
an increase in markers of podocyte damage, such as B7-1 and
desmin. Treatment with eplerenone dramatically improved
podocyte damage and retarded progression of proteinuria
and glomerulosclerosis.
Although 25 mg spironolactone appeared to be well
tolerated in this population at increased risk for hyper-
kalemia, owing to stage 3–4 CKD and co-administration of
ACEIs and ARBs, caution should be exercised when using
this drug in patients with eGFR below 60 ml/min. The low
incidence of hyperkalemia in our study might be due to close
clinical observation, adjustment of dietary intake of potas-
sium and dose of diuretics and should not be taken as an
indication for liberalized use of this drug in CKD patients.
Our study has several limitations. Although we observed
lower degree of progression of CKD in patients treated with
spironolactone, the number of patients included and the
duration of the study were not adequate to clearly establish a
long-term beneficial effect of spironolactone on progression
of kidney disease. Prospective randomized trials on larger
groups of patients and longer duration than 1 year are
necessary to more adequately address this issue.
The study was open label and not placebo controlled.
Therefore, potential bias in the evaluation of data cannot be
completely excluded. Finally, the limitations of using eGFR
instead of measured GFR are well known and have been the
object of extensive reviews.50,51
In conclusion, this study has demonstrated that antago-
nists of aldosterone reduce proteinuria in patients with CKD.
This effect occurs in addition to that obtained with the
administration of inhibitors of the RAS. The study also
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suggests that spironolactone may reduce the rate of
progression of CKD. However, larger prospective randomized
studies of longer duration are needed to conclusively
demonstrate beneficial effects of aldosterone antagonists on
the progression of CKD. Concerns remain in regards to the
risk of hyperkalemia particularly in patients with more
advanced kidney disease.
MATERIALS AND METHODS
This is a prospective, open-label randomized study to evaluate the
effects of spironolactone on proteinuria and eGFR and the safety of
this drug in CKD patients. The Human Research Committee of the
Spedali Riuniti di Livorno, Italy, approved the study and all subjects
gave their informed consent. The randomization was performed
using a computed generated system.
The clinical characteristics of patients included in the study are
illustrated in Tables 1 and 2. We enrolled 165 CKD patients (106
males and 59 females) with eGFR ranging from 34 to 116 ml/min/
1.73 m2 and proteinuria ranging from 1.0 to 3.9 g/g creatinine. These
subjects were screened among more than 400 patients with CKD
followed in our outpatient clinic. To be included, all patients had to
have a clinical diagnosis of idiopathic chronic glomerulonephritis
based on the presence of proteinuria greater than 1.0 g/g creatinine,
and no evidence of systemic diseases. In 62 of these patients, the
diagnosis of chronic glomerulonephritis was confirmed by a renal
biopsy: 33 patients had IgA nephropathy, five membrano-prolifera-
tive glomerulonephritis, 14 focal and segmental glomerulosclerosis,
eight membranous glomerulonephritis, and two had micro-
scopic vasculitis. In patients who were not biopsied, we cannot
exclude the possibility of renal diseases other than glomerulone-
phritis.
One hundred and twenty-two patients were hypertensive (office
systolic BPX140 mmHg and diastolic BPX90 mmHg). We excluded
patients with diabetes mellitus, renovascular or malignant hyper-
tension, secondary glomerular disease, malignancies, myocardial
infarction, or cerebrovascular accident within the 6 months prece-
ding the study, congestive heart failure, hepatic dysfunction, serum
potassium 45 mEq/l, eGFRo30 ml/min/1.73 m2, and a history
of allergy to ACEIs or ARBs. We also excluded patients treated
with steroids, nonsteroidal anti-inflammatory drugs, or immuno-
suppressive agents.
Before inclusion in this trial, all patients had been followed in the
outpatient clinic for at least 1 year and treated with ACEIs and/or
ARBs. In the control group, 21 subjects were treated with ACEIs,
18 with ARBs, and 43 with a combination of these two classes of
drugs. In the spironolactone group, 28 patients were treated with
ACEIs, 17 with ARBs and 38 with a combination of ACEIs and
ARBs. Fifty-six patients in the conventional therapy group and 60 in
the spironolactone group received hydrochlorothiazide or furose-
mide. Other antihypertensive drugs were used as needed to achieve a
target BP of o125/75 mmHg, and 74 patients achieved this target.
The doses of ACEIs and ARBs were not changed after randomization
and inclusion in the study. The dose of diuretics was increased in
patients who developed hyperkalemia in an attempt to control
serum potassium before deciding to withdraw patients from the
study. Seventy-two patients in the conventional therapy group and
74 in the spironolactone group received atorvastatin (20–40 mg/day)
for at least 1 year before the initiation of this study. Patients were
advised to ingest a diet with approximately 2–3 g sodium per day,
and if eGFR was lower than 60 ml/min/1.73 m2, they were counseled
to ingest a protein intake of 0.8 g/kg/day. We did not measure
urinary sodium and urea excretion to assess compliance with these
dietary restrictions.
The baseline evaluation included measurements of BP, heart rate,
urine protein excretion, eGFR, and plasma aldosterone levels. After
the baseline evaluation, 83 patients were randomized to receive
spironolactone 25 mg/day and 82 continued conventional therapy.
Thereafter, patients were seen in the clinic after 1, 3, 6, 9, and 12
months. At each clinic visit, BP and heart rate were measured at least
three times after sitting for 30 min and a blood sample was drawn.
At each clinic visit, including the baseline evaluation, each subject
was asked to bring three spot morning urine samples obtained on 3
consecutive days for the measurement of urine protein/creatinine
ratio. The average of these three samples was recorded.
Analytic procedures
BP was measured by mercury sphygmomanometer. Body mass index
(BMI) was calculated as weight (kg) divided by height (m) squared.
Urinary protein, serum creatinine, and potassium were measured
by standard methods. Glomerular filtration rate was estimated using
the Modification of Diet in Renal Disease formula.52 Plasma
aldosterone was measured by a commercially available kit (Nichols
Advantage Aldosterone, Nichols Institute Diagnostics, San Clem-
ente, CA, USA).
For statistical analysis, we used the Student’s t-test for parametric
parameters and the Kolmogorov–Smirnov test for comparison of
non-parametric parameters. We used univariate analyses to assess
correlations between baseline urinary protein excretion and eGFR,
age, gender, systolic and diastolic BP, percent change in urinary
protein excretion, and plasma aldosterone levels. Any covariates that
were significant in univariate analyses were assessed by step-wise
multiple linear regression analyses. Changes in urine protein
excretion, office BP, and eGFR were analyzed by repeated-measures
analysis of variance.
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